Cargando…

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma

BACKGROUND: Sorafenib was the first Food and Drug Administration approved anti-angiogenic therapy for renal cell carcinoma (RCC). Currently, there are no validated predictive biomarkers for sorafenib. Our purpose was to determine if sorafenib target expression is predictive of sorafenib sensitivity....

Descripción completa

Detalles Bibliográficos
Autores principales:	Aziz, Saadia A, Sznol, Joshua A, Albiges, Laurence, Zito, Christopher, Jilaveanu, Lucia B, Camp, Robert L, Escudier, Bernard, Kluger, Harriet M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896780/ https://www.ncbi.nlm.nih.gov/pubmed/24423208 http://dx.doi.org/10.1186/1475-2867-14-4

Ejemplares similares

Vascularity of primary and metastatic renal cell carcinoma specimens
por: Aziz, Saadia A, et al.
Publicado: (2013)

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
por: Aziz, Saadia A, et al.
Publicado: (2013)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
por: Weiss, Sarah A., et al.
Publicado: (2020)

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
por: Baine, Marina K., et al.
Publicado: (2015)

Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma
por: Oria, Victor O., et al.
Publicado: (2022)

Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma
por: Derosa, Lisa, et al.
Publicado: (2016)

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel
por: Jilaveanu, Lucia B., et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
por: Shuch, Brian, et al.
Publicado: (2015)

19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA
por: Oria, Victor, et al.
Publicado: (2020)

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells
por: Zito, Christopher R., et al.
Publicado: (2012)

Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma
por: Guida, Annalisa, et al.
Publicado: (2020)

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
por: Kluger, Harriet M, et al.
Publicado: (2007)

[(11)C]Methionine and [(11)C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis
por: Tran, Thuy T., et al.
Publicado: (2020)

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
por: Schoenfeld, David A., et al.
Publicado: (2022)

IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway
por: Ding, Xiaoyan, et al.
Publicado: (2018)

A role for the NPM1/PTPN14/YAP axis in mediating hypoxia-induced chemoresistance to sorafenib in hepatocellular carcinoma
por: Zhang, Dengke, et al.
Publicado: (2022)

The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib
por: Wang, Wen-Quan, et al.
Publicado: (2014)

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
por: Damsky, William, et al.
Publicado: (2019)

Golgi phosphoprotein 3 promotes angiogenesis and sorafenib resistance in hepatocellular carcinoma via upregulating exosomal miR-494-3p
por: Gao, Ying, et al.
Publicado: (2022)

Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma
por: Su, David, et al.
Publicado: (2023)

High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma
por: Xu, Jianjun, et al.
Publicado: (2022)

A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
por: Schoenfeld, David, et al.
Publicado: (2023)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK–Mfn2 signaling pathway
por: Song, Jie, et al.
Publicado: (2019)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
por: Elfiky, Aymen A, et al.
Publicado: (2011)

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
por: Jilaveanu, L.B., et al.
Publicado: (2014)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Tumour microvessel density as predictor of chemotherapy response in breast cancer patients
por: Tynninen, O, et al.
Publicado: (2002)

Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy
por: Tran, Thuy T., et al.
Publicado: (2019)

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
por: Oza, Bhavna, et al.
Publicado: (2022)

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Sznol, Mario, et al.
Publicado: (2015)

Stabilization of metastatic myxopapillary ependymoma with sorafenib
por: Fegerl, Gundula, et al.
Publicado: (2012)

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

Demographic and clinical predictors of depressive symptoms among incarcerated women
por: Pinese, Carmen SV, et al.
Publicado: (2010)

Sentinel events and predictors of suicide among inpatients at psychiatric hospitals
por: Chen, Yi-Lung, et al.
Publicado: (2012)

Adjustment of Microvessel Area by Stromal Area to Improve Survival Prediction in Non-Small Cell Lung Cancer
por: Fang, Luo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lngh9o5tv7hu9sl2qk39hkp7km